ADC Therapeutics (ADCT) Enterprise Value (2020 - 2026)

ADC Therapeutics has disclosed Enterprise Value across 7 years of filings, most recently posting -$82.7 million for Q2 2026.

• In Q2 2026, Enterprise Value fell 324.02% year-over-year to -$82.7 million; the TTM figure through Jun 2026 stood at -$82.7 million (down 324.02% YoY), while the FY2025 annual figure was $182.6 million, up 437.24% from the prior year.
• Enterprise Value came in at -$82.7 million for Q2 2026 at ADC Therapeutics, down from $245.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $697.5 million in Q1 2022 to a low of -$230.3 million in Q3 2023.
• Average Enterprise Value over 5 years is $50.0 million, with a median of -$3.0 million recorded in 2022.
• Year-over-year, Enterprise Value tumbled 2065.51% in 2023 and jumped 681.73% in 2025.
• Over 5 years, Enterprise Value stood at -$16.8 million in 2022, then tumbled by 746.51% to -$142.0 million in 2023, then jumped by 61.88% to -$54.1 million in 2024, then surged by 437.24% to $182.6 million in 2025, then slumped by 145.33% to -$82.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$82.7 million in Q2 2026, $245.9 million in Q1 2026, and $182.6 million in Q4 2025.